Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. April 2021 10:55 ET | Quelle: Biosplice Therapeutics, Inc.

Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform

New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice’s clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its...
01. Dezember 2020 10:00 ET | Quelle: Samumed, LLC.

Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering therapeutics based on RNA alternative splicing for major diseases, announced today that...
01. Juni 2020 11:00 ET | Quelle: Samumed, LLC.

Michael White, Ph.D. joins Samumed as Chief Scientific Officer

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced today that Dr. Michael White will...
22. Mai 2020 09:00 ET | Quelle: Samumed, LLC.

Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis

SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...